文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

hypo-FLAME试验:中高危前列腺癌局灶同步推量SBRT的急性毒性主要终点分析

Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.
PubMed 文献 · Radiother Oncol · 2020-04-01

hypo-FLAME是一项多中心前瞻性II期试验,入组100例中高危前列腺癌患者,全腺体SBRT 35 Gy/5次并同步对mpMRI可见肿瘤推量至50 Gy。主要终点为治疗相关急性毒性,未观察到≥3级急性泌尿或胃肠毒性,急性2级泌尿和胃肠毒性累积发生率分别为34.0%和5.0%。

要点

  • 全腺体35 Gy/5次同步肿瘤推量至50 Gy,未出现≥3级急性泌尿或胃肠毒性。
  • 治疗开始后90天,急性2级泌尿毒性累积发生率为34.0%,胃肠毒性为5.0%。
  • mpMRI可见肿瘤结节的中位平均剂量为44.7 Gy,急性毒性可接受。

核心结论

  • 全腺体前列腺SBRT同步对宏观肿瘤局灶推量,急性泌尿和胃肠毒性可接受。

研究设计与样本

  • 全腺体SBRT 35 Gy/5次每周,同步对mpMRI定义肿瘤推量至50 Gy,采用CTCAE v4.0评估毒性,主要终点为治疗相关急性毒性,随访至少6个月。

主要发现

  • 未观察到≥3级急性泌尿或胃肠毒性。
  • 治疗开始后90天,累积急性2级泌尿毒性发生率为34.0%,胃肠毒性为5.0%。
  • mpMRI可见肿瘤结节的中位平均剂量为44.7 Gy。

关键数值与推荐

  • 全腺体剂量35 Gy/5次,同步推量至50 Gy。
  • 急性2级泌尿毒性累积发生率34.0%,胃肠毒性5.0%。

临床怎么用

  • 中高危前列腺癌可考虑全腺体SBRT同步mpMRI可见肿瘤局灶推量,急性泌尿和胃肠毒性可接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Local recurrences after radiotherapy for prostate cancer (PCa) often originate at the location of the macroscopic tumour(s). Since PCa cells are known to be sensitive to high fraction doses, hypofractionated whole gland stereotactic body radiotherapy (SBRT) in conjunction with a simultaneous ablative microboost to the macroscopic tumour(s) within the prostate could be a way to reduce the risk of local failure. We investigated the safety of this treatment strategy. MATERIALS AND METHODS: Patients with intermediate or high risk PCa were enrolled in a prospective phase II trial, called hypo-FLAME. All patients were treated with extreme hypofractionated doses of 35 Gy in 5 weekly fractions to the whole prostate gland with an integrated boost up to 50 Gy to the multiparametric (mp) MRI-defined tumour(s). Treatment-related toxicity was measured using the CTCAE v4.0. The primary endpoint of the trial was treatment-related acute toxicity. RESULTS: Between April 2016 and December 2018, 100 men were treated in 4 academic centres. All patients were followed up for a minimum of 6 months. The median mean dose delivered to the visible tumour nodule(s) on mpMRI was 44.7 Gy in this trial. No grade ≥3 acute genitourinary (GU) or gastrointestinal (GI) toxicity was observed. Furthermore, 90 days after start of treatment, the cumulative acute grade 2 GU and GI toxicity rates were 34.0% and 5.0%, respectively. CONCLUSION: Simultaneous focal boosting to the macroscopic tumour(s) in addition to whole gland prostate SBRT is associated with acceptable acute GU and GI toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Draulans C, van der Heide UA, Haustermans K, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020. PMID: 32247206. doi:10.1016/j.radonc.2020.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。